DBV Technologies (NASDAQ:DBVT) Share Price Crosses Below 50 Day Moving Average – Here’s Why

DBV Technologies S.A. (NASDAQ:DBVT) shares passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $17.34 and traded as low as $15.24. DBV Technologies shares last traded at $15.71, with a volume of 142,942 shares traded.

Analyst Upgrades and Downgrades

DBVT has been the subject of several analyst reports. Guggenheim reissued a “buy” rating and issued a $51.00 price objective on shares of DBV Technologies in a research note on Monday, May 4th. Citizens Jmp lifted their target price on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research report on Tuesday, June 30th. HC Wainwright reiterated a “buy” rating on shares of DBV Technologies in a report on Tuesday, June 30th. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research report on Friday, May 1st. Finally, Wall Street Zen downgraded shares of DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 4th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, DBV Technologies has an average rating of “Moderate Buy” and an average target price of $48.50.

DBV Technologies Stock Performance

The company has a market capitalization of $870.39 million, a P/E ratio of -3.30 and a beta of -0.95. The stock has a 50 day moving average price of $17.24 and a 200 day moving average price of $19.51.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings results on Thursday, July 16th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.48). DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%. The company had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.78 million. As a group, sell-side analysts expect that DBV Technologies S.A. will post -0.38 earnings per share for the current year.

Institutional Investors Weigh In On DBV Technologies

Several institutional investors have recently added to or reduced their stakes in DBVT. Allworth Financial LP purchased a new stake in shares of DBV Technologies during the 4th quarter valued at approximately $32,000. Royal Bank of Canada bought a new position in shares of DBV Technologies in the fourth quarter valued at approximately $34,000. GAMMA Investing LLC grew its stake in DBV Technologies by 38.4% during the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after acquiring an additional 744 shares in the last quarter. Truvestments Capital LLC grew its position in shares of DBV Technologies by 71.3% during the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after purchasing an additional 1,620 shares in the last quarter. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of DBV Technologies in the fourth quarter worth $115,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.